News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
24-Nov-2008 - Biovitrum AB and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN) that can occur in RhD-negative mothers carrying a RhD-positive fetus. ...
Running R&D expenses estimated to be reduced by MSEK 115 on a rolling twelve-month basis
19-May-2008 - Biovitrum AB announced that it has completed the review of its research and development organization as announced in November 2007, when the company's new business strategy was initiated. In the new strategy, Biovitrum will focus on specialist care pharmaceuticals, as well as taking its projects ...
21-Apr-2008 - Biovitrum AB and Symphogen A/Sannounced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy volunteers. Clearance of red blood cells by RhD ...
Triggers milestone payment from Biovitrum
07-Apr-2008 - Biovitrum AB is in clinical phase II with the Kiobrina project and the first preterm infant has been recruited. This triggers a milestone payment from Biovitrum. Kiobrina(TM) is a recombinant, biotechnically produced human enzyme (BSSL) that breaks down fat in the intestine. Kiobrina is intended ...
28-Mar-2008 - Peter Edman, PhD, Associate Professor, 54, will join Biovitrum as Chief Scientific Officer. He is leaving his current position as Vice President and Global Project Director, Global Development, at AstraZeneca. Peter Edman has previously held a number of senior research leadership positions ...
06-Mar-2008 - Biovitrum AB and Syntonix Pharmaceuticals, Inc. have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of a long-acting, recombinant Factor IXFc for the treatment of Hemophilia B. The US Food and Drug Administration (FDA) has approved the ...
15-Feb-2008 - Biovitrum has completed a first explorative clinical Phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist intended for the treatment of glaucoma. The preliminary results show a dose dependent reduction of the intraocular pressure; a reduction that amounted to 10% as compared to ...
Initiates the Process to Find Partners for Its Early Stage Primary Care Projects
08-Feb-2008 - In November 2007, the management of the Swedish biopharma company Biovitrum announced a new strategy for creating long-term value and turning Biovitrum into a focused pharmaceutical company concentrated on specialist care projects. As a consequence of this decision, Biovitrum has now initiated a ...
07-Feb-2008 - Biovitrum and Symphogen announced the completion of a phase I clinical trial to test the safety and tolerability of Sym001 in healthy volunteers. The results from the dose-escalation, placebo-controlled study show that Sym001 is well tolerated. Sym001 is a recombinant, polyclonal antibody ...
21-Dec-2007 - A clinical phase I trial of BVT.74316 has now been successfully completed. This first clinical study, with the objective to test safety and tolerability in escalating single-dose and repeated-dose administration was started in August 2006. In total, 98 healthy volunteers have participated in the ...
© 1997-2024 LUMITOS AG, All rights reserved